Back to search results

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality, China

    Contact: Study coordinator (Zhi-Ming Shao, MD) · zhimingshao@yahoo.com · 86-21-641755901105
    Contact: Study coordinator (Lei Fan, MD) · cmchen@medmail.com.cn · 86-21-641755901105
    Contact: Principal Investigator (Zhi-Ming Shao, MD)
    Min He, MD (Sub-investigator)
    Linxiaoxi Ma, MD (Sub-investigator)
    Ying Zhou (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)